Bullous congenital ichthyosiform erythroderma: Safe and effective topical treatment with calcipotriol ointment in a child [3]

Acta Dermato-Venereologica

Volumn 83, Issue 1, 2003, Pages 52-54

  Bogenrieder, Thomas ^a   Landthaler, Michael ^a   Stolz, Wilhelm ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIPOTRIOL; CALCIUM; DERMATOLOGICAL AGENT; EMOLLIENT AGENT; ETRETIN; ETRETINATE; GLYCEROL; LACTIC ACID; RETINOIC ACID; SODIUM CHLORIDE; UREA;

AUTOSOMAL DOMINANT INHERITANCE; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CASE REPORT; CHROMOSOME 12Q; CHROMOSOME 17Q; CHROMOSOME MUTATION; CLINICAL EXAMINATION; CLINICAL FEATURE; CONGENITAL ICHTHYOSIFORM ERYTHRODERMA; CONTROLLED STUDY; DISEASE COURSE; DISTRESS SYNDROME; DRUG EFFICACY; DRUG SAFETY; ELECTRON MICROSCOPY; FAMILY HISTORY; HISTOLOGY; HUMAN; LETTER; MALE; OINTMENT; PRIORITY JOURNAL; SCHOOL CHILD; TOPICAL TREATMENT; TREATMENT FAILURE; TREATMENT OUTCOME; URINARY EXCRETION;

ADMINISTRATION, TOPICAL; CALCITRIOL; CHILD; DERMATOLOGIC AGENTS; HUMANS; HYPERKERATOSIS, EPIDERMOLYTIC; MALE; OINTMENTS;

EID: 0037275025     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: 10.1080/00015550310002738     Document Type: Letter

References (15)

1. Compton JG, DiGiovanna JJ, Santucci SK, Kearns KS, Amos CI, Abangan DL, et al. Linkage of epidermolytic hyperkeratosis to the type II keratin gene cluster on chromosome 12q. Nat Genet 1992; 1: 301-305.
2. Rothnagel JA, Dominey AM, Dempsey LD, Longley MA, Greenhalgh DA, Gagne TA, et al. Mutations in the rod domains of keratins 1 and 10 in epidermolytic hyperkeratosis. Science 1992; 257: 1128-1130.
3. Cheng J, Syder AJ, Yu QC, Letai A, Paller AS, Fuchs E. The genetic basis of epidermolytic hyperkeratosis: a disorder of differentiation-specific epidermal keratin genes. Cell 1992; 70: 811-819.
4. Fuchs E, Esteves RA, Coulombe PA. Transgenic mice expressing a mutant keratin 10 gene reveal the likely genetic basis for epidermolytic hyperkeratosis. Proc Natl Acad Sci USA 1992; 89: 6906-6910.
5. Kragballe K, Steijlen PM, Ibsen HH, van de Kerkhof PC, Esmann J, Sorensen LH, et al. Efficacy, tolerability, and safety of calcipotriol ointment in disorders of keratinization. Results of a randomized, double-blind, vehicle-controlled, right/left comparative study. Arch Dermatol 1995; 131: 556-560.
6. Fritsch PO. Retinoids in psoriasis and disorders of keratinization. J Am Acad Dermatol 1992; 27: S8-14.
7. Halkier-Sorensen L, Laurberg G, Andresen J. Bone changes in children on long-term treatment with etretinate. J Am Acad Dermatol 1987; 16: 999-1006.
8. Glover MT, Peters AM, Atherton DJ. Surveillance for skeletal toxicity of children treated with etretinate. Br J Dermatol 1987; 116: 609-614.
9. Smith EL, Walworth NC, Holick MF. Effect of 1alpha,25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol 1986; 86: 709-714.
10. Russell S, Young MJ. Hypercalcaemia during treatment of psoriasis with calcipotriol [letter]. Br J Dermatol 1994; 130: 795-796.
11. Hoeck HC, Laurberg G, Laurberg P. Hypercalcaemic crisis after excessive topical use of a vitamin D derivative. J Intern Med 1994; 235: 281-282.
12. Lucker GP, van de Kerkhof PC, van Dijk MR, Steijlen PM. Effect of topical calcipotriol on congenital ichthyoses. Br J Dermatol 1994; 131: 546-550.
13. Perez A, Chen TC, Turner A, Raab R, Bhawan J, Poche P, Holick MF. Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin D3) for the treatment of psoriasis. Br J Dermatol 1996; 134: 238-246.
14. Haas AA, Arndt KA. Selected therapeutic applications of topical tretinoin. J Am Acad Dermatol 1986; 15: 870-877.
15. Carlberg C, Bendik I, Wyss A, Meier E, Sturzenbecker LJ, Grippo JF, et al. Two nuclear signalling pathways for vitamin D. Nature 1993; 361: 657-660.